Source link : https://newshealth.biz/health-news/fda-bmd-can-be-surrogate-endpoint-in-osteoporosis-trials/
The FDA greenlights treatment-related changes in bone mineral density as a surrogate endpoint in anti-osteoporosis drug trials in postmenopausal women. Medscape Medical News Source link : https://www.medscape.com/viewarticle/fda-bmd-can-be-surrogate-endpoint-osteoporosis-trials-2025a100102r?src=rss Author : Publish date : 2025-12-23 09:35:00 Copyright for syndicated content belongs to the linked Source.
The post FDA: BMD Can Be Surrogate Endpoint in Osteoporosis Trials first appeared on News Health.
—-
Author : News Health
Publish date : 2025-12-23 09:35:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8